Therapeutics that block inhibitory checkpoints or activate stimulatory checkpoints have proven to be effective in restoring anti-tumor immune responses and treating cancer in recent years. In particular, the FDA-approved drugs targeting immune checkpoints like cytotoxic T-lymphocyte antigen (CTLA-4), programmed cell death (PD-1), and its ligand (PD-L1) to treat various types...